These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27765799)

  • 81. Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers.
    Zheng Y; Zou J; Sun C; Peng F; Peng C
    Front Mol Biosci; 2023; 10():1165781. PubMed ID: 37251081
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Irreversible tyrosine kinase inhibitors induce the endocytosis and downregulation of ErbB2.
    Ghosh C; Xing Y; Cai J; Sun Y
    Biochem Biophys Rep; 2023 Jul; 34():101436. PubMed ID: 36824069
    [TBL] [Abstract][Full Text] [Related]  

  • 83. In Silico Identification of Genes Associated with Breast Cancer Progression and Prognosis and Novel Therapeutic Targets.
    Uchida S; Sugino T
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428562
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Global signalling network analysis of luminal T47D breast cancer cells in response to progesterone.
    Wright RHG; Vastolo V; Oliete JQ; Carbonell-Caballero J; Beato M
    Front Endocrinol (Lausanne); 2022; 13():888802. PubMed ID: 36034422
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer.
    Lau TY; Kwan HY
    Mar Drugs; 2022 May; 20(6):. PubMed ID: 35736173
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells.
    Chen Y; Xu J; Pan W; Xu X; Ma X; Chu Y; Wang L; Pang S; Li Y; Zou B; Zhou G; Gu J
    Thorac Cancer; 2022 Jul; 13(13):1961-1973. PubMed ID: 35599381
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
    Madera S; Izzo F; Chervo MF; Dupont A; Chiauzzi VA; Bruni S; Petrillo E; Merin SS; De Martino M; Montero D; Levit C; Lebersztein G; Anfuso F; Roldán Deamicis A; Mercogliano MF; Proietti CJ; Schillaci R; Elizalde PV; Cordo Russo RI
    Cell Death Dis; 2022 May; 13(5):447. PubMed ID: 35534460
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The BA-BCS 2021: An Initial "Trial" for Integrating Basic Science and Medical Progress on Breast Cancer in a Latin-American Country.
    Kordon E; Lanari C; Mando P; Novaro V; Rossi M; Simian M
    J Mammary Gland Biol Neoplasia; 2021 Sep; 26(3):227-234. PubMed ID: 34642841
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Comprehensive Analysis of the Expression and Prognostic Value of SPINT1/2 in Breast Carcinoma.
    Wu Q; Yin G; Luo J; Zhang Y; Ai T; Tian J; Jin Y; Lei J; Liu S
    Front Endocrinol (Lausanne); 2021; 12():665666. PubMed ID: 34381422
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Nuclear ErbB2 represses DEPTOR transcription to inhibit autophagy in breast cancer cells.
    Bi Y; Gong L; Liu P; Xiong X; Zhao Y
    Cell Death Dis; 2021 Apr; 12(4):397. PubMed ID: 33854045
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The molecular basis of mammary gland development and epithelial differentiation.
    Slepicka PF; Somasundara AVH; Dos Santos CO
    Semin Cell Dev Biol; 2021 Jun; 114():93-112. PubMed ID: 33082117
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance.
    Zhang Y
    Pharmacol Ther; 2021 Feb; 218():107677. PubMed ID: 32898548
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth.
    Chervo MF; Cordo Russo RI; Petrillo E; Izzo F; De Martino M; Bellora N; Cenciarini ME; Chiauzzi VA; Santa María de la Parra L; Pereyra MG; Güttlein LN; Podhajcer OL; Daniotti JL; Dupont A; Barchuk S; Figurelli S; Lopez Della Vecchia D; Roa JC; Guzmán P; Proietti CJ; Schillaci R; Elizalde PV
    Oncogene; 2020 Sep; 39(39):6245-6262. PubMed ID: 32843720
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Applying the New Guidelines of HER2 Testing in Breast Cancer.
    Zhang H; Moisini I; Ajabnoor RM; Turner BM; Hicks DG
    Curr Oncol Rep; 2020 Apr; 22(5):51. PubMed ID: 32346807
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Dynamic gene regulation by nuclear colony-stimulating factor 1 receptor in human monocytes and macrophages.
    Bencheikh L; Diop MK; Rivière J; Imanci A; Pierron G; Souquere S; Naimo A; Morabito M; Dussiot M; De Leeuw F; Lobry C; Solary E; Droin N
    Nat Commun; 2019 Apr; 10(1):1935. PubMed ID: 31028249
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
    Feng Y; Spezia M; Huang S; Yuan C; Zeng Z; Zhang L; Ji X; Liu W; Huang B; Luo W; Liu B; Lei Y; Du S; Vuppalapati A; Luu HH; Haydon RC; He TC; Ren G
    Genes Dis; 2018 Jun; 5(2):77-106. PubMed ID: 30258937
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Targeting HER2 in Nuclear Medicine for Imaging and Therapy.
    Massicano AVF; Marquez-Nostra BV; Lapi SE
    Mol Imaging; 2018; 17():1536012117745386. PubMed ID: 29357745
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Risk Factors and Preventions of Breast Cancer.
    Sun YS; Zhao Z; Yang ZN; Xu F; Lu HJ; Zhu ZY; Shi W; Jiang J; Yao PP; Zhu HP
    Int J Biol Sci; 2017; 13(11):1387-1397. PubMed ID: 29209143
    [TBL] [Abstract][Full Text] [Related]  

  • 99. High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia.
    Fu L; Fu H; Qiao J; Pang Y; Xu K; Zhou L; Wu Q; Li Z; Ke X; Xu K; Shi J
    Cancer Sci; 2017 Sep; 108(9):1850-1857. PubMed ID: 28670859
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.
    Knutson TP; Truong TH; Ma S; Brady NJ; Sullivan ME; Raj G; Schwertfeger KL; Lange CA
    J Hematol Oncol; 2017 Apr; 10(1):89. PubMed ID: 28412963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.